Stoke Therapeutics Target of Unusually High Options Trading (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) was the target of unusually large options trading activity on Friday. Traders bought 10,008 call options on the stock. This represents an increase of 1,407% compared to the typical daily volume of 664 call options.

Wall Street Analysts Forecast Growth

A number of research firms have commented on STOK. JPMorgan Chase & Co. upped their price target on Stoke Therapeutics from $15.00 to $25.00 and gave the company a "neutral" rating in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Stoke Therapeutics in a research note on Wednesday. Chardan Capital raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday. Wedbush boosted their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 5th. Finally, Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $31.00.

View Our Latest Analysis on Stoke Therapeutics

Stoke Therapeutics Trading Up 3.0%

STOK stock traded up $0.83 during mid-day trading on Friday, reaching $28.76. The company's stock had a trading volume of 118,917 shares, compared to its average volume of 909,724. The company has a market cap of $1.64 billion, a price-to-earnings ratio of 42.93 and a beta of 1.32. The business's 50 day moving average price is $27.41 and its 200 day moving average price is $18.21. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.11). The business had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. As a group, equities analysts expect that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Adrian R. Krainer sold 40,472 shares of the company's stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $26.98, for a total value of $1,091,934.56. Following the completion of the transaction, the director directly owned 364,246 shares in the company, valued at approximately $9,827,357.08. This represents a 10.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 10,000 shares of the firm's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total transaction of $250,700.00. Following the transaction, the general counsel directly owned 11,831 shares of the company's stock, valued at $296,603.17. The trade was a 45.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 213,367 shares of company stock valued at $5,110,464. 9.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC bought a new stake in Stoke Therapeutics in the second quarter valued at $7,489,000. Wellington Management Group LLP grew its stake in shares of Stoke Therapeutics by 438.2% in the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company's stock valued at $17,337,000 after buying an additional 600,687 shares during the period. Polar Capital Holdings Plc grew its stake in shares of Stoke Therapeutics by 49.8% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company's stock valued at $31,102,000 after buying an additional 439,824 shares during the period. Checkpoint Capital L.P. increased its position in Stoke Therapeutics by 139.3% in the 1st quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company's stock valued at $4,859,000 after buying an additional 425,330 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new position in Stoke Therapeutics during the 1st quarter worth approximately $2,670,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Read More

• Five stocks we like better than Stoke Therapeutics
• Bank Stocks - Best Bank Stocks to Invest In
• Walmart Stock Surges After a Solid Q3—Stronger Growth Ahead
• Best Aerospace Stocks Investing
• Microsoft’s AI Superfactory Could Power a Stock Rally
• Best Stocks Under $10.00
• 3 Big Tech Stocks Sliding: What’s Behind the Drop?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stoke Therapeutics Right Now?

Before you consider Stoke Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.

While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here